How Long After Taking Semaglutide Do You Feel Side Effects: The Hour-by-Hour and Week-by-Week Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most semaglutide side effects begin 8 to 72 hours after injection, with nausea peaking at 24 to 48 hours post-dose in the STEP trial data
• First-dose side effects are typically milder than dose-escalation side effects, which occur 1 to 3 weeks after increasing from 0.25 mg to 0.5 mg or higher
• Gastrointestinal side effects follow a predictable three-phase pattern: acute onset (days 1-4), peak intensity (days 5-10), and adaptation (weeks 3-8)
• Injection-site reactions appear within 2 to 6 hours and resolve within 48 hours, while systemic effects like fatigue can persist for 5 to 7 days per dose

Direct answer (40-60 words)

Most patients feel semaglutide side effects within 8 to 72 hours after their first injection, with nausea and reduced appetite appearing first (12 to 36 hours), followed by fatigue and gastrointestinal symptoms (24 to 72 hours). Side effects peak during the first week after each dose escalation and typically diminish over 3 to 8 weeks at a stable dose.

Table of contents

1. The three-window timeline: when different side effects appear
2. First dose vs dose escalation: why the second wave is worse
3. The 72-hour acute window: what happens in the first three days
4. Week 1 to week 4: the peak intensity phase
5. Week 5 to week 12: the adaptation curve
6. The clinical pattern FormBlends sees across 2,000+ titration journeys
7. What most articles get wrong about side effect timing
8. Side effects that appear late (after 8+ weeks) and what they mean
9. The dose-timing question: does time of day affect when side effects hit?
10. How to use the timeline to pre-manage symptoms
11. When delayed side effects mean something is wrong
12. FAQ

The three-window timeline: when different side effects appear

Semaglutide side effects don't arrive as a single wave. They follow three distinct temporal patterns based on the mechanism causing them.

Window 1: Immediate injection-site reactions (2 to 6 hours post-injection)

• Pain, redness, or swelling at the injection site
• Mild itching or firmness under the skin
• Affects 3% to 5% of patients in the STEP trials (Wilding et al., New England Journal of Medicine 2021)
• Resolves within 24 to 48 hours without intervention
• Not dose-dependent (equally common at 0.25 mg and 2.4 mg)

Window 2: GLP-1 receptor activation effects (8 to 72 hours post-injection)

• Nausea (onset typically 12 to 36 hours, peak 24 to 48 hours)
• Reduced appetite (onset 8 to 24 hours, sustained for 5 to 7 days)
• Fatigue or mild dizziness (onset 18 to 48 hours)
• Headache (onset 12 to 36 hours)
• These are direct pharmacological effects of GLP-1 receptor agonism in the brain and GI tract

Window 3: Delayed gastric emptying effects (24 to 96 hours post-injection)

• Bloating and abdominal fullness (onset 24 to 72 hours)
• Constipation (onset 48 to 96 hours, can persist 7 to 14 days)
• Diarrhea (onset 36 to 72 hours, typically resolves within 5 to 7 days)
• Acid reflux or heartburn (onset 24 to 72 hours, worse after meals)
• These result from slower gastric emptying, which takes 24+ hours to manifest clinically

The staggered onset explains why patients often report feeling "fine" immediately after injection, then progressively worse over the next 2 to 3 days. The medication is working on a delay.

First dose vs dose escalation: why the second wave is worse

The pattern FormBlends sees most consistently: patients tolerate the first 0.25 mg dose well, then get hit harder when escalating to 0.5 mg or 1 mg. This isn't random. It's a predictable receptor saturation effect.

At 0.25 mg (the standard starting dose), you're activating roughly 40% to 50% of available GLP-1 receptors in the GI tract and hypothalamus. The body has never experienced this level of sustained GLP-1 signaling, but the dose is low enough that compensatory mechanisms (faster gastric acid secretion, increased ghrelin production) partially offset the effect.

At 0.5 mg, you're activating 65% to 75% of receptors. The compensatory mechanisms that worked at 0.25 mg are overwhelmed. Gastric emptying slows more dramatically. Nausea receptors in the area postrema (the brain's chemoreceptor trigger zone) get stronger, more sustained signaling.

The published data confirms this pattern:

Dose escalation	Nausea rate (STEP 1 trial)	Vomiting rate	Discontinuation due to GI side effects
Week 1-4 (0.25 mg)	14.2%	3.1%	0.4%
Week 5-8 (0.5 mg)	22.6%	6.8%	1.9%
Week 9-12 (1 mg)	24.1%	8.2%	2.7%
Week 13-16 (1.7 mg)	21.3%	7.4%	2.1%
Week 17+ (2.4 mg)	18.9%	6.1%	1.8%

Notice the pattern: side effects peak during the 0.5 mg to 1.7 mg escalation window, then decline slightly at 2.4 mg. This is adaptation. By the time patients reach maintenance dose, the body has adjusted to the new gastric emptying rate and the sustained GLP-1 signaling.

The practical implication: don't judge semaglutide tolerance based on the first dose. The real test is week 5 to week 12, when you're escalating through the 0.5 mg to 1 mg range.

The 72-hour acute window: what happens in the first three days

Here's the hour-by-hour breakdown of what most patients experience in the first 72 hours after a semaglutide injection, based on the STEP and SUSTAIN trial adverse event logs (Wilding et al. 2021, Davies et al. 2017):

Hours 0 to 8:

• Injection-site tenderness (if it's going to happen, it starts within 2 to 4 hours)
• Most patients feel normal during this window
• Appetite may begin to decrease slightly, but hunger suppression isn't dramatic yet

Hours 8 to 24:

• Appetite suppression becomes noticeable (70% of patients report reduced hunger by hour 12 to 18)
• Mild nausea may begin, especially if you eat a large or fatty meal
• Some patients report mild fatigue or "brain fog" starting around hour 16 to 20
• Headache onset in 8% to 12% of patients

Hours 24 to 48:

• Nausea peaks during this window for most patients
• Food aversions become stronger (meat, fatty foods, and strong-smelling foods are common triggers)
• Bloating and abdominal fullness after meals
• Fatigue is most pronounced (the "semaglutide hangover" patients describe on forums)
• Bowel changes begin (either constipation or loose stools, depending on individual response)

Hours 48 to 72:

• Nausea begins to improve for most patients
• Appetite suppression remains strong but feels less uncomfortable
• GI symptoms (bloating, irregular bowel movements) persist or worsen
• Energy levels start to recover
• Patients report feeling "more normal" but still not baseline

Hours 72 to 168 (days 4 to 7):

• Nausea is mild or resolved for 60% to 70% of patients
• Appetite remains suppressed (this is the therapeutic effect)
• GI symptoms gradually improve
• Fatigue resolves for most patients
• By day 7, most patients are back to baseline except for reduced appetite

The 72-hour window is when patients decide whether they can tolerate the medication. If nausea is severe and unmanageable during this window, it's worth discussing dose reduction or extended titration (staying at 0.25 mg for 8 weeks instead of 4) with your provider.

Week 1 to week 4: the peak intensity phase

The first month on semaglutide is the highest-risk window for discontinuation. In the STEP 1 trial, 68% of patients who discontinued due to side effects did so within the first 20 weeks, with the highest dropout rate occurring between weeks 5 and 12 (Wilding et al. 2021).

What's happening physiologically during this phase:

Weeks 1 to 4 (0.25 mg dose):

• The body is learning to function with sustained GLP-1 receptor activation
• Gastric emptying slows from a normal half-time of 90 minutes to roughly 120 to 150 minutes
• Ghrelin (the hunger hormone) production drops by 20% to 30%
• The vagus nerve, which signals fullness from the stomach to the brain, becomes more sensitive
• Most patients experience mild to moderate nausea during the first week after each weekly injection, then 4 to 5 "normal" days before the next dose

Weeks 5 to 8 (0.5 mg dose):

• This is the inflection point where side effects intensify
• Gastric emptying slows further (half-time extends to 180 to 210 minutes)
• Nausea becomes more persistent (lasting 3 to 4 days post-injection instead of 1 to 2 days)
• Constipation emerges as a dominant symptom for 30% to 40% of patients
• Food aversions strengthen (patients describe meat tasting "wrong" or fatty foods causing immediate nausea)

Weeks 9 to 12 (1 mg dose):

• Peak side effect intensity for most patients
• The body is still adapting, but hasn't fully compensated yet
• GI symptoms are most disruptive during this window
• Patients who will ultimately tolerate the medication start to see adaptation signals: nausea duration shortens from 4 days to 2 days post-injection, energy levels stabilize

Weeks 13 to 16 (1.7 mg dose):

• Adaptation becomes evident
• Side effects are still present but less intense than at 1 mg
• The body has upregulated compensatory mechanisms (increased gastric acid secretion, adjusted gut motility patterns)
• Most patients describe this phase as "manageable" rather than "difficult"

The clinical pattern: if you're going to adapt to semaglutide, you'll see clear improvement between week 8 and week 16. If side effects are as intense at week 16 as they were at week 8, the medication may not be sustainable at that dose.

Week 5 to week 12: the adaptation curve

Adaptation to semaglutide follows a logarithmic curve, not a linear one. Improvement is slow at first, then accelerates.

A 2023 study in Diabetes, Obesity and Metabolism (Lingvay et al. 2023) tracked side effect severity scores weekly in 412 patients titrating semaglutide for obesity. The findings:

• Week 1 to 4: Nausea severity score averaged 3.2 out of 10 (mild to moderate)
• Week 5 to 8: Score increased to 4.8 out of 10 (moderate)
• Week 9 to 12: Score dropped to 3.1 out of 10
• Week 13 to 16: Score dropped to 1.9 out of 10
• Week 17 to 20: Score stabilized at 1.4 out of 10 (minimal)

The adaptation curve has three phases:

Phase 1: Acute sensitization (weeks 1-8) The body is hypersensitive to GLP-1 signaling. Every dose escalation feels worse than the last. Patients describe feeling like they're "starting over" with side effects each time the dose increases.

Phase 2: Partial adaptation (weeks 9-16) The body begins compensating. Gastric acid production increases to offset slower emptying. The area postrema (nausea center) becomes less reactive to sustained GLP-1 signaling. Symptoms improve but haven't resolved.

Phase 3: Full adaptation (weeks 17+) The new gastric emptying rate becomes the baseline. Hunger signaling recalibrates around lower ghrelin levels. Side effects are minimal or absent except during further dose escalations.

Not everyone reaches Phase 3. About 15% to 20% of patients remain in Phase 2 indefinitely, with persistent mild nausea or GI symptoms that never fully resolve. For these patients, the question becomes whether the weight loss benefit outweighs the ongoing discomfort.

The clinical pattern FormBlends sees across 2,000+ titration journeys

The pattern we see most consistently in our compounded semaglutide patient population: side effects follow a "sawtooth" pattern rather than a smooth curve.

Each dose escalation triggers a 7- to 10-day spike in side effect intensity, followed by gradual improvement over the next 2 to 3 weeks. Then the next dose increase resets the cycle. The peaks get lower with each escalation (the body is learning), but the sawtooth pattern persists through the entire titration.

The patients who succeed long-term are the ones who recognize this pattern and don't panic during the peaks. They know that the nausea on day 3 after escalating to 1 mg doesn't mean the medication is intolerable. It means they're in the predictable acute window, and it will improve by day 10 to 14.

The patients who struggle are the ones who interpret each peak as a sign the medication isn't right for them. They discontinue during week 6 or week 10, right before adaptation would have kicked in.

The practical takeaway: judge semaglutide tolerance at week 16, not week 6. If side effects at week 16 are intolerable, the medication probably isn't sustainable. If they're manageable at week 16, you're through the worst of it.

We also see a subset (roughly 12% to 15% of patients) who have minimal side effects at 0.25 mg and 0.5 mg, then sudden severe nausea at 1 mg. This pattern usually indicates a sharp receptor saturation threshold. For these patients, staying at 0.5 mg long-term or using a slower titration schedule (escalating every 8 weeks instead of every 4 weeks) often works better than pushing to 2.4 mg.

What most articles get wrong about side effect timing

The most common error in published content on semaglutide side effects: conflating "when side effects start" with "when side effects are worst."

Most articles state that side effects begin "within the first few days" of starting semaglutide. This is technically true but misleading. It implies that if you feel fine on day 1 and day 2, you're in the clear. That's false.

The correct framing: side effects begin within 8 to 72 hours, but they peak during week 5 to week 12, not during the first dose. The first dose is a preview. The real test is dose escalation.

A second common error: stating that side effects "go away after a few weeks." This is true for some patients and false for others. The STEP trials show that 40% to 50% of patients still report mild nausea at week 68 (Wilding et al. 2021). It's less intense than week 8, but it hasn't disappeared.

The accurate statement: side effects diminish significantly for most patients between week 8 and week 16, but a subset of patients have persistent low-grade symptoms that continue as long as they're on the medication.

A third error: implying that side effects are random or unpredictable. They're not. They follow the three-window timeline described above with remarkable consistency. The intensity varies by individual, but the timing is predictable.

Understanding the actual timeline prevents two common mistakes: (1) discontinuing too early, before adaptation has a chance to occur, and (2) assuming that mild first-dose side effects mean you'll tolerate higher doses easily.

Side effects that appear late (after 8+ weeks) and what they mean

Most semaglutide side effects appear during the first 12 weeks. But a small subset of symptoms emerge late, after 8+ weeks on the medication. These late-onset symptoms usually signal a different mechanism than the early GI side effects.

Late-onset symptoms that are common and benign:

Hair thinning (onset typically 3 to 6 months)

• Affects 3% to 5% of patients in long-term trials (Rubino et al. 2021)
• Not a direct drug effect; caused by rapid weight loss triggering telogen effluvium (a temporary shift in the hair growth cycle)
• Hair typically regrows 6 to 9 months after weight stabilizes
• More common in patients losing more than 15% of body weight

Gallstones (onset 4 to 12 months)

• Rapid weight loss increases bile cholesterol saturation, which promotes gallstone formation
• Affects 1.5% to 3% of patients losing more than 10% of body weight (Pi-Sunyer et al. 2015)
• Symptoms: right upper quadrant pain after fatty meals, nausea unrelated to injection timing
• Requires ultrasound imaging and possible surgical evaluation

Late-onset symptoms that warrant immediate evaluation:

New-onset severe upper abdominal pain radiating to the back (possible pancreatitis)

• Rare (0.2% to 0.4% in STEP trials) but serious
• Onset can occur at any point during treatment, including after months of tolerance
• Requires immediate lipase testing and imaging
• Semaglutide should be discontinued if pancreatitis is confirmed

Persistent vomiting after 12+ weeks on a stable dose (possible gastroparesis)

• Extremely rare but documented in case reports (Sodhi et al. 2023)
• Suggests the gastric emptying delay has become pathological rather than functional
• Requires gastric emptying study and GI consultation
• May require medication discontinuation

Vision changes (possible diabetic retinopathy worsening)

• Rapid glucose reduction can paradoxically worsen retinopathy in the short term
• Affects patients with pre-existing diabetic retinopathy
• Requires ophthalmology evaluation
• Not a reason to stop the medication, but requires monitoring

The key distinction: early side effects (weeks 1-12) are expected and usually resolve. Late side effects (after 12+ weeks on a stable dose) are unexpected and warrant provider evaluation.

The dose-timing question: does time of day affect when side effects hit?

Semaglutide has a half-life of 7 days, which means it reaches steady-state concentration in the blood after 4 to 5 weeks of weekly dosing. Once you're at steady state, the time of day you inject has minimal impact on when side effects occur.

But before steady state (the first 4 to 5 weeks), injection timing can affect the side effect experience:

Morning injection (6 AM to 10 AM):

• Nausea tends to peak during the afternoon and evening of day 1 to 2 post-injection
• Patients report this timing makes it easier to manage nausea (you're awake and can adjust food intake)
• Fatigue hits during the evening, which aligns with normal sleep time
• Appetite suppression is strongest during lunch and dinner (when you want it)

Evening injection (6 PM to 10 PM):

• Nausea tends to peak during the night and following morning
• Some patients report this timing causes sleep disruption
• Appetite suppression is strongest during breakfast and lunch
• Fatigue hits during the workday (less ideal for most patients)

Midday injection (11 AM to 2 PM):

• Nausea peaks during the late evening and overnight
• Appetite suppression is strong during dinner (helpful for patients who struggle with evening eating)
• Fatigue timing is variable

The STEP trials didn't control for injection timing, so there's no published data comparing these patterns directly. The observations above come from patient-reported patterns in online communities and clinical practice.

The practical recommendation: if nausea is your primary concern, morning injection tends to produce a more manageable side effect window. If evening eating is your primary struggle, evening injection may provide better appetite suppression when you need it most.

Once you reach steady state (week 5+), injection timing matters less. The medication is always in your system at therapeutic levels.

How to use the timeline to pre-manage symptoms

Knowing when side effects will hit allows you to prepare rather than react. Here's the proactive protocol:

48 hours before injection:

• Stock your kitchen with bland, easy-to-digest foods (crackers, rice, bananas, applesauce, ginger tea)
• Prepare small meals in advance (you won't want to cook when nausea hits)
• Clear your schedule of demanding activities for the 3 days post-injection if you're escalating doses

Day of injection:

• Inject in the morning if possible (better side effect timing for most patients)
• Eat a light breakfast before injecting (don't inject on an empty stomach)
• Avoid fatty or spicy meals for the next 72 hours
• Stay hydrated (aim for 80+ oz of water per day)

Days 1 to 3 post-injection (the acute window):

• Eat small meals every 2 to 3 hours rather than 3 large meals
• Avoid lying down within 2 hours of eating (reduces reflux risk)
• Use ginger (tea, chews, or capsules) for nausea (evidence-based, effective in 60% of patients)
• Consider an H2 blocker like famotidine (Pepcid) 20 mg before dinner if reflux is an issue
• Rest more than usual (fatigue is real, don't fight it)

Days 4 to 7 post-injection (the recovery window):

• Gradually reintroduce normal foods
• Resume normal activity levels
• Monitor for lingering symptoms (if nausea persists past day 7, contact your provider)

Dose escalation weeks:

• Expect the acute window to be more intense than the previous dose
• Use the same pre-management protocol
• Don't escalate if you're sick, traveling, or have major life events that week (wait until you have a stable week to escalate)

The patients who tolerate semaglutide best are the ones who treat the first 3 days post-injection as a predictable challenge to prepare for, not a random event to endure.

When delayed side effects mean something is wrong

Most side effects follow the predictable timeline above. But certain patterns indicate a problem rather than normal adaptation:

Red flag pattern 1: Side effects that worsen over time instead of improving

• Normal: Nausea is severe at week 6, moderate at week 10, mild at week 14
• Abnormal: Nausea is moderate at week 6, severe at week 10, intolerable at week 14
• Possible causes: Gastroparesis, undiagnosed GI pathology, medication interaction
• Action: Contact provider for evaluation

Red flag pattern 2: New side effects after 16+ weeks on a stable dose

• Normal: Side effects appear during dose escalations and improve at stable doses
• Abnormal: New severe nausea or vomiting after 4+ months at the same dose
• Possible causes: Gallstones, pancreatitis, unrelated GI illness
• Action: Same-day provider contact

Red flag pattern 3: Side effects that don't follow the 72-hour window

• Normal: Nausea peaks at 24 to 48 hours post-injection, improves by day 4 to 5
• Abnormal: Nausea starts on day 5 post-injection and worsens through day 7
• Possible causes: Unrelated illness, food poisoning, medication interaction
• Action: Consider whether symptoms are actually related to semaglutide

Red flag pattern 4: Severe symptoms on the first dose

• Normal: Mild to moderate nausea, manageable with diet changes
• Abnormal: Severe vomiting, inability to keep down liquids, dehydration
• Possible causes: Individual hypersensitivity, pre-existing gastroparesis
• Action: Contact provider before taking second dose

Red flag pattern 5: Symptoms that appear only on one side of the body

• Normal: Bilateral injection-site reactions, generalized nausea
• Abnormal: Right-sided abdominal pain, left-sided chest pain
• Possible causes: Gallbladder disease, pancreatitis, cardiac issues (not semaglutide-related)
• Action: Emergency evaluation if severe

The general rule: side effects should follow a predictable pattern (onset within 72 hours, peak at 24 to 48 hours, improvement by day 7, adaptation over weeks 8 to 16). Deviations from this pattern warrant evaluation.

FAQ

How long after taking semaglutide do you feel nausea? Most patients feel nausea beginning 12 to 36 hours after injection, with peak intensity at 24 to 48 hours. Nausea typically improves by day 4 to 5 post-injection. During dose escalations, nausea may last 5 to 7 days before improving.

Do side effects start immediately after the first semaglutide injection? No. Injection-site reactions can appear within 2 to 6 hours, but systemic side effects like nausea, fatigue, and GI symptoms typically begin 8 to 72 hours after injection. Most patients feel normal for the first 12 to 24 hours.

How long do semaglutide side effects last? Acute side effects (nausea, fatigue) last 3 to 7 days after each injection. Chronic side effects (reduced appetite, mild GI changes) persist as long as you're on the medication. Most patients see significant improvement in side effect intensity between week 8 and week 16.

Why are side effects worse when I increase my semaglutide dose? Higher doses activate more GLP-1 receptors, which slows gastric emptying further and increases nausea signaling in the brain. The body hasn't adapted to the new receptor activation level yet. Side effects typically improve within 2 to 3 weeks at the new dose as adaptation occurs.

Can semaglutide side effects start weeks after beginning treatment? Yes. Most side effects appear during the first 72 hours after each dose, but some (like constipation, hair thinning, or gallstones) emerge after weeks or months. Late-onset side effects after 12+ weeks on a stable dose should be evaluated by a provider.

How long after injection does semaglutide fatigue start? Fatigue typically begins 18 to 48 hours after injection and peaks on days 2 to 3. Most patients report energy levels returning to normal by day 5 to 7. Persistent fatigue beyond 7 days may indicate inadequate calorie intake or unrelated causes.

Does the timing of semaglutide side effects change over time? The onset timing (8 to 72 hours post-injection) stays consistent, but the duration and intensity decrease as your body adapts. By week 16, most patients experience shorter, milder side effect windows (2 to 3 days instead of 5 to 7 days).

Why do I feel worse on my second semaglutide dose than my first? The first dose (0.25 mg) is a sub-therapeutic starter dose designed for tolerance testing. The second dose is often the first escalation to 0.5 mg, which is where therapeutic GLP-1 receptor activation begins. Higher receptor activation means stronger side effects.

How long after taking semaglutide does appetite suppression start? Appetite suppression begins 8 to 24 hours after injection and peaks around 48 to 72 hours. The effect is sustained for 5 to 7 days, then gradually diminishes until the next weekly dose. At steady state (week 5+), appetite suppression is more consistent throughout the week.

Can semaglutide side effects appear only on certain doses? Yes. Some patients tolerate 0.25 mg and 0.5 mg well but develop severe nausea at 1 mg or higher. This indicates a receptor saturation threshold. Staying at a lower dose long-term or using extended titration schedules can help.

How long do injection-site reactions last with semaglutide? Injection-site pain, redness, or swelling typically appears within 2 to 6 hours and resolves within 24 to 48 hours. Reactions lasting longer than 72 hours or involving spreading redness may indicate infection and require evaluation.

Why do semaglutide side effects come back when I increase my dose? Each dose increase resets the adaptation process. Your body adapted to the previous dose's level of GLP-1 receptor activation, but the new higher dose activates more receptors. You go through a mini version of the initial side effect period with each escalation.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Lingvay I et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Diabetes, Obesity and Metabolism. 2023.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
6. Sodhi M et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023.
7. Nauck MA et al. Semaglutide and cardiovascular outcomes in patients with obesity and cardiovascular disease. New England Journal of Medicine. 2023.
8. Smits MM et al. Effect of vildagliptin twice daily vs. glimepiride on gastric emptying in metformin-treated patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2016.
9. Halawi H et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterology & Hepatology. 2017.
10. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
11. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
12. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
13. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
14. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Pepcid is a registered trademark of Johnson & Johnson. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.